| dc.description.abstract |
Background: cervical cancer is the fourth most common cancer in women. Human papilloma
virus vaccines were distributed to a single cohort of 14-year-old girls in Ethiopia. Therefore, the
study aimed to assess acceptance of HPV vaccination among mothers of daughters in Arba
Minch Zuria woreda, Arbaminch, Ethiopia.
Objective: The main objective of this study was to assess acceptance of human papilloma virus
vaccination and its associated factors among mothers of daughters in Arba Minch Zuria woreda
Gamo zone, southern Ethiopia in 2022.
Methods and materials: Community based cross - sectional study design was applied from May
17 to June17, 2022 on 410 mothers of daughters aged 9 to 17 years selected by systematic
random sampling method. Two stage sampling method was applied to select 414 mothers of
daugthers in Arba Minch Zuria woreda. Stata version 14 was used to perform descriptive
statistics for tabular and graphic presentation of the findings. P-value ≤0.25 was used to identify
candidate variables in binary logistic regression, and p-value <0.05 was used to describe the
relationship between dependent and independent variables in multivariable analysis.
Result: Overall, 71.2% (95% CI: 66.8, 75.6) of the participants accepted the HPV vaccine for
their daughters. Having moderate and good knowledge about cervical cancer (AOR=4.9, 95% CI
2.8, 8.6), (AOR=1.9, 95% CI 1, 3.6), positive attitude (AOR=2.6, 95% CI 1.4, 4.9), good
knowledge of HPV infection and vaccine, (AOR=1.6, 95% CI 1.01 , 2.78), wealth index
(AOR=2.1, 95% CI 1.14, 3.9) and being educated (AOR=2.8 95% CI 1.4 ,5.7) were significantly
associated with HPV vaccination acceptance.
Conclusion: The acceptance of the HPV vaccine was optimal in the area. Positive attitude
towards the HPV vaccine, educational status, knowledge of cervical cancer, HPV infection and
vaccine, and wealth index were significantly associated with the HPV vaccine acceptance.
Sustainable and coordinated awareness-creation program should be implemented to improve
HPV vaccine acceptance. |
en_US |